What is Anticancer Bioscience?
Anticancer Bioscience, headquartered in Ghengdu, China, is a pioneering medtech company dedicated to advancing precision oncology. The firm specializes in developing innovative synthetic lethal approaches, a sophisticated strategy aimed at selectively targeting cancer cells while sparing healthy ones. This focus positions Anticancer Bioscience at the forefront of personalized cancer treatment, leveraging cutting-edge biotechnology to address unmet medical needs in the oncology sector.
How much funding has Anticancer Bioscience raised?
Anticancer Bioscience has raised a total of $41M across 2 funding rounds:
Other Financing Round
$10M
Angel/Seed
$31M
Other Financing Round (2021): $10M, investors not publicly disclosed
Angel/Seed (2021): $31M, investors not publicly disclosed
What's next for Anticancer Bioscience?
The substantial enterprise-level backing indicates a strategic inflection point for Anticancer Bioscience. This influx of capital is anticipated to fuel further research and development, potentially accelerating clinical trials and expanding the company's therapeutic pipeline. The company is poised to leverage this investment to solidify its market position and drive innovation in synthetic lethal therapies, aiming to bring novel precision oncology treatments to patients worldwide.
See full Anticancer Bioscience company page
